SCIO-469，5MG，SML3008-5MG，Sigma

Biochem/physiol Actions

Orally active, potent and selective mitogen-activated protein kinase (MAPK) p38alpha (p38α, MAPK14) inhibitor in vitro and in vivo.
SCIO-469 (Talmapimod) is an orally active, potent and selective mitogen-activated protein kinase (MAPK) p38alpha (p38α, MAPK14) inhibitor (IC50 = 9 nM; 10-fold over p38β, >2000-fold over 20 other kinases) with no significant affinity toward a panel of 70 enzymes and receptors. SCIO-469 inhibits multiple myeloma (MM) growth in mice in vivo (150 or 450 mg/kg powder diet; 5T2MM and 5T33MM) and augments proteasome inhibitor in a murine plasmacytoma model of MM (0.2 mg bortezomib/kg i.v. twice weekly with 30 mg SCIO-469/kg b.i.d. p.o.; RPMI8226).